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Abstract: In this report, the enantioselective, copper-catalyzed borylation of β-amidoacrylates is disclosed. A broad variety of bio-
logically important α-aminoboronates has been prepared with consistently high levels of enantiocontrol, using an inexpensive copper 
catalyst and a commercially available chiral ligand. The method can be applied to the synthesis of novel boron-containing dipeptides 
and hemiboronates. 
Chiral α-aminoboronic acids have become an important class 
of biologically active compounds, notably due to their use as 
proteasome inhibitors.[1] The α-aminoboronic acid motif is pre-
sent in the approved anticancer drugs bortezomib (Velcade®) 
and Ixazomib (Ninlaro®) or in phase I/II candidates such as 
Delanzomib (Figure 1). Additionally, these structures have also 
been used as intermediates for the synthesis of enantiomerically 
enriched amines or amino alcohols.[2] 
 
Figure 1. Biologically active α-aminoboronates 
Despite their biological relevance and synthetic interest, the 
asymmetric synthesis of α-aminoboronates has been mostly 
based on diastereoselective methods that involve the use of stoi-
chiometric amounts of chiral auxiliaries.[3] Although a few ef-
fective catalytic methods have been reported, they still present 
structural limitations (Scheme 1). For instance, the metal-cata-
lyzed[4] and metal-free borylation[5] of imines and enamines[6] 
only allow the preparation of aryl-substituted  α-aminoboro-
nates (Scheme 1, eq 1). Alternatively, the copper-catalyzed hy-
droamination of alkenes overcomes this restriction, but only 
compounds with dialkylamino groups can be prepared (Scheme 
1, eq 2).[7] However, α-aminoboronates shown in Figure 1 have 
two structural features in common:  a secondary amide with an 
amino acid residue and an alkyl substituent α to the aminoboro-
nate moiety. Therefore, we realized that the development of cat-
alytic asymmetric methods to introduce these two structural 
motifs simultaneously remains an important unmet challenge.  
Scheme 1. Enantioselective catalytic approaches to α-aminoboro-
nates 
 
To address this task, we turned our attention to Z-enamides 
of type A as potential precursors of α-aminoboronates B 
through an enantioselective copper-catalyzed borylation 
(Scheme 1, eq 3). We reasoned that the hydrogen bond between 
the N-H and the carbonyl could provide a rigid template for the 
development of an effective asymmetric transformation. Addi-
tionally, Z-enamides can be easily prepared as single stereoiso-
mers. The products would be a novel class of α-aminoboronates 
that contain the two structural motifs present in biologically ac-
tive compounds: the secondary amide moiety and an alkyl sub-
stituent with a functional group susceptible to further function-
alization. Moreover, from a biological point of view, they could 
also benefit from being b-amino acid derivatives.[8] Importanly, 
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 the transformation would represent the first copper-catalyzed 
borylation of a β-amidoacrylate.[9],[10] 
To test our hypothesis, we prepared enamide 1a through pal-
ladium-catalyzed addition of benzamide to ethyl propiolate.[11] 
We next examined the copper-catalyzed borylation[12] of 1a in 
the presence of a variety of chiral phosphines.[13] Enamide 1a 
was treated in THF, at room temperature, with CuCl (10 mol 
%), B2pin2 (1.1 equiv), NaOt-Bu (1 equiv), MeOH (4 equiv) and 
11 mol % of a chiral ligand. After some optimization, we found 
that (R)-Segphos provided the highest yield and the best enan-
tiomeric ratio (Scheme 2).  
Scheme 2. Optimized copper-catalyzed borylation  
 
One of the main challenges we encountered during the re-
action optimization was the moderate stability of compound 2a 
on silica gel. Although the 1H NMR of the crude products 
showed clean conversion, 2a was consistently obtained in low 
yields. Standard deactivation of the silica gel with trimethyla-
mine did not work. After significant effort, we found that it was 
essential to deactivate the silica gel with 30 weight % of water 
to obtain high yields.  
We next explored the scope of the method with different Z-
enamides (Table 1). Aryl enamides with electron-donating 
(Table 1, entry 2) and electron-withdrawing groups in the para, 
meta and ortho positions (Table 1, entries 3-6) afforded α-ami-
noboronates 2b-2f in high yields and excellent enantiomeric 
ratios. Heteroaromatic substituted enamides, with coordinating 
atoms such as sulfur and nitrogen, were also suitable substrates 
for the borylation.  Importantly, alkyl amides such as 2i and N-
Boc protected α-aminoboronate 2j could be also prepared with 
excellent stereoselectivity (Table 1, entries 9-10). Finally, we 
were pleased to find that this catalytic system also worked 
when we substituted the ester moiety for a peptide bond (Table 
1, compounds 2k, 2l).[14] On the contrary, the enantiomeric ex-
cess dropped down significantly when ketones were tested. Fi-
nally, using 5 mol % of CuCl, we observed lower yields in most 
cases.   
Next, we tested the present catalytic system with a more 
challenging substrate such as 1m (Scheme 3), with a phenyl al-
anine fragment structurally close to the anticancer agent borte-
zomib I (Scheme 1). Using the standard reaction conditions and 
(R)-DM-Segphos as a chiral ligand, the borylated product 2m 
was obtained with moderate dr,  
Table 1. Substrate scope of Z-enamides 1  
 
entry[a] product er[b] yield (%)[c] 
1 
 
98:2 96 
2 
 
96:4 77 
3 
 
96:4 68 
4 
 
95:5 71 
5 
 
96:4 76 
6 
 
91:9     69 
7 
 
95:5 76 
8 
 
96:4 60 
9 
 
94:6 67 
10 
 
97:3 49 
11[e] 
 
˃99:1 67 
12[d,e] 
 
97:3 96 
[a] Reaction conditions: 1 (0.2 mmol), B2pin2 (0.22 mmol, 1.1 equiv), NaOt-Bu (1.0 
equiv), CuCl (10 mol %), L2 (11 mol %), MeOH (0.8 mmol, 4.0 equiv), THF (0.1 M). 
[b] The er was determined by chiral HPLC. [c] Isolated yield. [d]  1.5 equiv of B2pin2 was 
used.  [e] The reaction time was 12 h.  
revealing a possible mismatched scenario (Scheme 4). Indeed, 
the use of (S)-DM-Segphos, provided the matched diastereomer 
2m’ with improved diastereomeric ratio.  
 
 
Scheme 3. Synthesis of boron-containing dipeptides 
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Table 2. Substrate scope of E-enamides 3 
 
entry[a] product er[b] yield (%)[c] 
1[d] 
 
96:4 68 
2[e] 
 
95:5 70 
3[e] 
 
95:5 65 
4[e] 
 
92:8 56 
5[d] 
 
95:5 73 
6[e] 
 
91:9 70 
7[e,f] 
 
95:5 65 
8[e] 
 
91:9 59 
9[d] 
 
91:9 38 
[a] Reaction conditions: 3 (0.2 mmol), B2pin2 (0.22 mmol, 1.1 equiv), NaOt-Bu (1.0 
equiv), CuCl (10 mol %), L2 (11 mol %), MeOH (0.8 mmol, 4.0 equiv), THF (0.1 M). 
[b] The er was determined by chiral HPLC. [c] Yield of isolated 4. [d] The reaction time 
was 4 h.  [e] The reaction time was 12 h. [f] The reaction was performed at -20 °C.  
We further expanded the scope of our method to N-Boc-
protected E-enamides 3, with an alkyl substituent and a remov-
able protecting group on the nitrogen (Table 2). Gratifyingly, 
our catalytic system proved to be robust despite the significant 
structural changes. N-Boc protected benzylic (4a-4b) and het-
erobenzylic (4c-4d) derivatives were prepared in good yields 
and high enantiomeric ratio, with the opposite configuration at 
the aminoboro stereocenter compared to compounds 2.[15] Sim-
ple alkyl chains on the nitrogen  (4e) as well as b-carboxylate 
groups (4f) were also tolerated. E-Enamides with a benzylic es-
ter were also suitable substrates for the copper-catalyzed 
borylation, affording compounds 4g and 4h in good yields and 
high stereocontrol. Finally, α-aminoboronate 4i was prepared in 
moderate yield, showing that the benzoyl group on the nitrogen 
is less efficient for the E-enamide series  
To provide compounds more suitable for biological appli-
cations, we removed the pinacol ester moiety (Scheme 4). 
Treatment of α-aminoboronate 2a with KHF2 afforded tri-
fluoroborate salt 5 in excellent yield. Interestingly, hydrolysis 
of the pinacol boronic ester in 2a resulted in formation of hem-
iboronate 6. However, when the same hydrolysis conditions 
were applied to amide 2j, boronic acid 7 was obtained in good 
yield. Importanly, N-Boc protected derivative 2i was trans-
formed into primary α-aminoboronate 8.  
Scheme 4. Removal of the pinacol ester  
 
Finally, we performed DFT calculations to gain insight into 
the mechanism of the reaction and to account for the observed 
stereoselectivity (Figure 2). We started from Cu(I)-boryl com-
plex C, using (R)-Segphos and (S)-Segphos as ligands, and en-
amide E. We introduced a methyl group at the enamide instead 
of an ethyl group to simplify the calculation. The reaction be-
gins with the initial endothermic complexation of chiral copper-
boryl complex C and enamide E. Two metal-ƞ2-alkene com-
plexes are initially formed, with Complex-S resulting slightly 
lower in energy than Complex-R. The borylation reaction is a 
highly exoergic (-26.9 kcal mol-1) and, therefore, irreversible 
process (Figure 2). Consequently, the enantioselectivity of the 
process is kinetically controlled in the insertion step. Two tran-
sition states for the boryl cupration (TS-R and TS-S) were lo-
cated and permitted the calculation of the corresponding activa-
tion energies for the formation of both enantiomers. Im-
portantly, calculated TS-R showed a 9.7 Kcal mol-1 lower ener-
getic barrier than TS-S (Figure 2), consistent with the formation 
of the observed major enantiomer using ligand (R)-L2.[16] Fi-
nally, once the C-B bond and the stereochemistry has been de-
fined, the copper is stabilized forming a copper enolate. These 
results suggest the insertion as the rate-limiting step, as well as 
the enantiodeterming step. 
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Figure 2. Energy profile for the enantioselective borylation pro-
cess. M06-2X/6-31G(d,p)-cc-pVDZ-DK(Cu)-
SMD(THF)//B3LYP/6-31G(d)-cc-pVDZ-DK(Cu)- SMD(THF). 
C-H bonds were omitted for clarity. All energies in kcal mol−1. For 
more detail, see Supporting Information.  
  
In summary, we have developed a novel catalytic approach 
for the preparation of enantiomerically enriched α-aminoboro-
nates. Our method has proven to be general for a wide variety 
of substrates, including the preparation of boryl containing di-
peptides, using an inexpensive copper catalyst and a commer-
cially available chiral ligand. Biologically studies of the pre-
pared compounds are underway. 
ASSOCIATED CONTENT  
Experimental procedures, compound characterization data, ana-
lytic details for all enantiomerically enriched products and crystal 
structural data. This material is available free of charge via the In-
ternet at http://pubs.acs.org.  
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